(1S,2R,3R,4R)-2-N-[[4-(1,1-difluoroethyl)-1,3-oxazol-2-yl]methyl]-3-N-(3-fluoropiperidin-4-yl)spiro[bicyclo[2.2.1]heptane-7,1'-cyclopropane]-2,3-dicarboxamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (1S,2R,3R,4R)-2-N-[[4-(1,1-difluoroethyl)-1,3-oxazol-2-yl]methyl]-3-N-(3-fluoropiperidin-4-yl)spiro[bicyclo[2.2.1]heptane-7,1'-cyclopropane]-2,3-dicarboxamide
• 化学式: C₂₂H₂₉F₃N₄O₃
• 分子量: 454.5
• InChiKey: BTJLXTMTKGXTHS-OBHWAKJYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  96.3
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• DIFLUOROETHYL-OXAZOLE SUBSTITUTED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP3013817B1

  公开（公告）日：2017-04-26
• Difluoroethyl-oxazole sustituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20160289221A1

  公开（公告）日：2016-10-06

  The present invention relates to difluoroethyl-oxazole substituted bridged spiro[2.4] heptane derivatives of formula (I), wherein the substituents at the piperidine ring are in trans-arrangement, their preparation and their use as pharmaceutically active compounds.